Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy

  • J Med Chem. 2026 Oct 8;69(19):22138-22161. doi: 10.1021/acs.jmedchem.6c01288.
Zhisheng Zhang  1 ,  Xuan Zhang  1 ,  Yinan Jiang  1 ,  Manqi Zhang  1 ,  Juan Zhao  2 ,  Tianxin Li  1 ,  Jiani Yang  1 ,  Shengnan Shi  1 ,  Xueling Cao  1 ,  Lingxiang Jiang  1 ,  Zihan Tian  1 ,  Yongsheng Wu  1 ,  Jiawen Ru  1 ,  Liuxiang Zhu  1 ,  Qianming Du  3 ,  Jinlei Bian  1 ,  Zhiyu Li  1 ,  Xi Xu  1 ,  Jubo Wang  1
Affiliations
  • 1. Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China.
  • 2. Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing211198, P. R. China.
  • 3. Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing210006, P. R. China.
Abstract

Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in Cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1/HDAC dual inhibitors as a single-molecule strategy for Cancer therapy. Through systematic structure-activity relationship studies and biochemical profiling, compound 58 was identified as a promising dual inhibitor with moderate GLS1 inhibition and potent HDAC activity, particularly against HDAC6. Compound 58 exhibited strong antiproliferative activity in multiple Cancer cell lines and modulated GLS1-associated glutamine metabolism and HDAC-related acetylation markers in cells. In a CT26 tumor-bearing mouse model, compound 58 achieved a tumor growth inhibition (TGI) rate of 91.10% without obvious systemic toxicity. Overall, this study supports GLS1/HDAC dual inhibition as a promising Anticancer strategy and provides compound 58 as a valuable lead for further optimization.

Keywords
GLS1; HDAC; antitumor; dual-target inhibitors.
Products